Recombinant Granulocyte Colony-Stimulating Factor

ApprovedBiologic

Recombinant Granulocyte Colony-Stimulating Factor is one of 210 biologic programs targeting Toxic Epidermal Necrolysis. It is currently in Approved.

Indications

Total Trials

Active Trials

209

Competitors

Pipeline

Status by Indication[3][1]

Indication

Toxic Epidermal NecrolysisActive, not recruiting

LymphomaActive, not recruiting

MyelofibrosisActive, not recruiting

Plasma Cell LeukemiaNot yet recruiting

Myelodysplastic SyndromeActive, not recruiting

Multiple MyelomaActive, not recruiting

Acute Myeloid LeukemiaCompleted

Chronic Myeloid Leukemia, BCR-ABL1 PositiveRecruiting

Acute Lymphoblastic Leukemia in RemissionRecruiting

Myeloid NeoplasmActive, not recruiting

Toxic Epidermal NecrolysisApproved

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

MyelofibrosisPhase 2

Active, not recruiting

Plasma Cell LeukemiaPhase 2

Not yet recruiting

Myelodysplastic SyndromePhase 1/Phase 2

Active, not recruiting

Multiple MyelomaApproved

Active, not recruiting

Acute Myeloid LeukemiaPhase 2

Completed

Chronic Myeloid Leukemia, BCR-ABL1 PositivePhase 1

Recruiting

Acute Lymphoblastic Leukemia in RemissionPreclinical

Recruiting

Myeloid NeoplasmPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Recombinant Granulocyte Colony-Stimulating Factor

FFred Hutchinson Cancer Center

Approved

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Oncaspar

SServier

Preclinical

15 5

Zofran

Novartis

Preclinical

2 6

Norvir

AbbVie

Preclinical

1 7

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 8

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 10

Nuvigil

NNuvo Research GmbH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Acute Myeloid Leukemia

NCT04797767

ApprovedRecruiting

Multiple Myeloma

NCT07101445

Q2 2029

Phase 1Recruiting

Chronic Myeloid Leukemia, BCR-ABL1 Positive

NCT07020533

Phase 2Recruiting

Acute Myeloid Leukemia

NCT07046078

Q3 2029

Phase 2Recruiting

Myelofibrosis

NCT04370301

Q4 2029

Phase 2Recruiting

Lymphoma

NCT04871607

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia4 trials

Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms

Terminated·UUniversity of Washington·Phase 1·NCT04196010·13 enrolled

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT07046078·20 enrolled

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Recruiting·UUniversity of Washington·Phase 1/2·NCT04797767·62 enrolled

Show 1 more trial

Randomized Phase 2 Trial of CPX-351 (Vyxeos) vs. CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less-Fit Adults With Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT04195945·60 enrolled

Myelofibrosis1 trial

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT04370301·20 enrolled

Toxic Epidermal Necrolysis1 trial

G-CSF in the Treatment of Toxic Epidermal Necrolysis

Completed·UUniversity of Liege·Phase 4·NCT02739295·10 enrolled

Myeloid Neoplasm1 trial

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT03531918·66 enrolled

Lymphoma1 trial

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

Recruiting·—·Phase 2·NCT04871607·33 enrolled

4 more indications

Chronic Myeloid Leukemia, BCR-ABL1 Positive1 trial

A Phase 1b Trial of CMV-MVA Triplex Vaccine in Haploidentical Stem Cell Donors and Recipients to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients of Hematopoietic Stem Cell Transplant

Recruiting·CCity of Hope Medical Center·Phase 1·NCT07020533·46 enrolled

Multiple Myeloma1 trial

Prevent Allergic Reactions to Aphexda With Dexamethasone (PARADE)

Recruiting·EEmory University·Approved·NCT07101445·94 enrolled

Plasma Cell Leukemia1 trial

Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT07605416·74 enrolled

Acute Lymphoblastic Leukemia in Remission1 trial

A Phase I/II Study Evaluating Escalating Doses of 211At-Labeled Anti-CD45 MAb BC8-B10 (211At-BC8-B10) Followed by Related Haplo-Identical Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Leukemia or Myelodysplastic Syndrome (MDS)

Recruiting·FFred Hutchinson Cancer Center·Preclinical·NCT03670966·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Recombinant Granulocyte Colony-Stimulating Factor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant Granulocyte Colony-Stimulating Factor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant Granulocyte Colony-Stimulating Factor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fred Hutchinson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: FFred Hutchinson Cancer Center

Recombinant Granulocyte Colony-Stimulating Factor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2029

Q3 2029

Q4 2029

Trials by Indication[1]

Acute Myeloid Leukemia4 trials

Myelofibrosis1 trial

Toxic Epidermal Necrolysis1 trial

Myeloid Neoplasm1 trial

Lymphoma1 trial

Chronic Myeloid Leukemia, BCR-ABL1 Positive1 trial

Multiple Myeloma1 trial

Plasma Cell Leukemia1 trial

Acute Lymphoblastic Leukemia in Remission1 trial

References

Drug Info

Quick Facts

Related News